Anesthesiology News 26th Annual Corporate Profiles

Available online @ AnesthesiologyNews.com

Corporate Profiles 18

Anesthesia Business Consultants

20

Arizant Healthcare Inc., a 3M Company

21

Cadence Pharmaceuticals

22

Dräger

24

Edwards Lifesciences

26

MAQUET Medical Systems USA

28

Masimo

30

MCMahon Publishing

31

Pacira Pharmaceuticals, Inc.

32

Plexus Information Systems, Inc.

34

Spacelabs Healthcare

36

TeamHealth Anesthesia

38

Teleflex

2013-2014

Corporate Profiles

ANNUAL

ANESTHESIA S S BUSINESS US SS CONSULTANTS CO SU S

A

nesthesia Business Consultants, LLC (ABC) is the largest billing and practice management company dedicated to the complex and intricate specialty of anesthesia and pain management. It is both an Anesthesia Quality Institute Preferred Vendor and a Gold Affiliate with the Medical Group Management Association. Tony Mira, ABC’s founder, president and CEO, has maintained a concentration on providing services exclusively to anesthesia and pain management professionals since the company’s inception more than 30 years ago.

ABC distinguishes itself by providing optimal business tools to strengthen business processes and enhance cash flow—all while keeping pace with constant changes in the health care environment. ABC prides itself on the longevity of its client relationships and its ability to customize services to the unique requirements of each practice.

ABC offers its clients innovative billing and reimbursement services, as well as valuable practice management tools and solutions that allow them to realize their own particular strategic visions and business plans.

The ABC Management Advantage ABC distinguishes itself through its focus, operational approach and management structure: • Unlike many competitors who continually redefine their market focus, ABC has remained true to its core market of anesthesiologists, certified registered nurse anesthetists and pain management specialists, enhancing the credibility of its insight and advice.

• ABC believes its relationship with its clients is a true partnership—a partnership in which ABC not only helps improve the billing process, but also helps the group operate more efficiently in the operating room, and more proactively in its relationship with the hospital.

• ABC’s centralized approach allows effective management and oversight, ensuring consistent results.

• Managing a business based on the input and expectations of shareholders does not always result in the most appropriate business decision making. Because ABC is privately held, it has much greater flexibility in setting its agenda, managing the business and being responsive to its clients’ needs.

The ABC Service Advantage ABC offers a full range of services designed to meet its clients’ needs, from a specific area of service to an all-encompassing solution partner.

Billing and Reimbursement Services Because all processing is centralized, ABC maintains its high standards for quality control and efficiency, resulting in faster claims resolution and

higher levels of reimbursement. Extensive management reporting options allow both management and client to monitor subtle changes in payer mix and reimbursement patterns. Services include: • Front-end edit and claim-scrubber technology • Patient deductible strategies and solutions • Claim underpayment monitoring and reporting

Management Support Services No one company is more qualified to furnish critical management information and proactively advise practice decision makers. ABC stands alone in its ability to provide a full range of management support services: • Strategic management • Practice management - Practice consulting - Financial services - Quality management (PQRS) - Human resources consulting - Contracting services - Compliance and HIPAA - Education and training

AT A GLANCE ADDRESS 255 West Michigan Ave. Jackson, MI 49201 Phone: (800) 242-1131 Fax: (517) 787-0529

WEBSITES www.anesthesiallc.com www.communiquenews.com

SOCIAL MEDIA http://www.anesthesiallc.com/ easyblog/latest http://twitter.com/AnesthesiaLLC https://www.facebook.com/ anesthesiallc http://www.linkedin.com/company/ anesthesia-business-consultants https://plus.google.com/10046113 4039781832016#100461134039 781832016/posts

The ABC Technology Advantage In order to ensure flexibility with its clients and their varying level of needs, ABC has carefully crafted a portfolio of products to meet its clients’ needs during the entire perioperative process.

The most advanced, secure and reliable software designed especially for anesthesia billing and practice management, F1RSTAnesthesia T ™ converts clinical information into claims for reimbursement. This powerful tool supports electronic claims editing to ensure consistently high billing acceptance rates and minimizes manual intervention in payment posting through direct remittance processing. Providers also are able to receive real-time or historical information through F1RSTAnesthesia T ’s web-based technology or advanced data warehousing/data-mining technology.

OneSourceAnesthesia is a powerhouse platform that offers an à la carte approach to the complete perioperative process—clients choose the features they need now, and have the peace of mind that comes from knowing OneSourceAnesthesia e is adaptable and that they can add increasing functionality as their needs grow and change.

The OneSourceAnesthesia e platform offers: - Patient portal - Electronic medical records (EMR) - Postoperative quality - Call scheduling - Patient satisfaction - Patient monitoring - Meaningful use The primary hardware tool required for ABC’s solution is an Apple iPad. The OneSourceAnesthesia e solution also requires no interaction with the hospital or surgery center’s servers to host the software in any way. These elements, when combined with the intuitive user experience of OneSourceAnesthesia, offer an unparalleled

SERVICES Full-service billing and practice management firm dedicated exclusively to anesthesiologists and pain management physicians.

EMPLOYEES 850+

platform to streamline and automatically incorporate best practices and clinical protocols to any practice.

• F1RSTUse is the first full-service electronic health records (EHR) management platform built exclusively for anesthesiologists and pain management specialists to satisfy stage 1 of meaningful use as required to earn the Medicare or Medicaid EHR incentive payment.

• The Provider Portal provides information you need to stay competitive and informed. The Provider Portal is now available to clients of ABC and takes advantage of the OneSourceAnesthesia e infrastructure to bring together systems such as: - Meaningful use EHR - Presurgical testing management - iPad EMR - Anesthesia call scheduling - Patient satisfaction surveys - Intraoperative patient monitoring - Anesthesia quality outcomes - OR utilization - Patient portal - Live chat

Tony Mira, President and CEO

18

Anesthesiology News • August 2013

This corporate profile was reviewed and approved by Anesthesia Business Consultants.

800.242.1131 info@anesthesiallc.com www.anesthesiallc.com

Make An Educated Decision Information You Need To Be Informed and Stay Competitive Anesthesia Business Consultants (ABC) believes the more you know, the better the decisions you can make.

ABC places the highest value on continuing education. As the health care world continues to evolve, offering new technological advances and business models, along with changing laws and regulations, it’s imperative to keep informed. We provide our clients and associates regular updates on what is happening in the world of anesthesiology through our weekly eAlerts. These Alerts highlight the very latest in developments, changing requirements and opportunities and are a complimentary service. If you are interested in receiving these Alerts just send your name, e-mail address, the name of your practice or company, city and state to info@anesthesiallc.com.

ABC is also pleased to offer the Communiqué, our quarterly newsletter, to interested individuals. It is available electronically as well as in print. The Communiqué features articles written by industry leaders focusing on the latest hot topics in group management, compliance and future business models for anesthesiologists, nurse anesthetists, pain management specialists and anesthesia practice administrators.

We look forward to providing you with many more years of practice management news through the Communiqué and our weekly Alerts.

Please log on to ABC’s web site at www.anesthesiallc.com and click on the “Publications” link to view the electronic version of the Communiqué online or to see copies of our previous Alerts.

ABC does not share this list with any third parties nor use it for purposes other than distributing the Alerts, the quarterly Communiqués and the very occasional special announcement. If you have any questions or would like additional information please call 517-787-6440 x 4113, send an email to info@anesthesiallc.com, or visit our website at www.anesthesiallc.com. This communication is for educational informational purposes only and is not intended or offered as legal advice.

2013-2014

Corporate Profiles

ANNUAL

ARIZANT HEALTHCARE C INC., C , A 33M COMPANY CO

S

ince the introduction of 3M™ Bair Hugger™ therapy in 1987, Arizant Healthcare Inc., a 3M company, has continuously developed patient warming solutions that set the standard for innovation and quality.

The introductions of the 3M™ Bair Paws™ patient adjustable warming gowns and 3M™ Ranger™ fluid warming systems highlight our commitment to develop ingeniously simple products that make it easier for clinicians to do their jobs while helping to improve patient care.

This year we proudly introduce our latest gamechanging technology—the 3M™ SpotOn™ temperature monitoring system—which offers clinicians a non-invasive method to measure patients’ core body temperature accurately throughout the perioperative journey using a single disposable sensor.

3M surgical warming products are safely and effectively used to maintain normothermia for more than 20 million patients each year. We look forward to continuing our partnership with you on the mission to improve patient outcomes through effective patient warming.

3M™ SpotOn™ System (www.SpotOnTemperature.com) The SpotOn temperature monitoring system represents a new standard in core temperature monitoring, simplifying the existing temperature measurement process while delivering accurate temperature measurement typically associated with more invasive methods, such as esophageal, bladder, rectal or PA catheters.

The SpotOn system utilizes a single-use sensor placed on the patient’s forehead in the pre-op setting. Temperature is continuously displayed on the system’s control unit, ensuring optimization of warming modalities through real-time temperature data.

In addition, a memory chip within the sensor provides a two-hour continuous visual representation of the patient temperature trend on the SpotOn control unit.

The sensor stays on the patient—disconnected from the sensor cable and reconnected to another SpotOn control unit at each point of care—to eliminate variability.

20

Anesthesiology News • August 2013

The SpotOn system also helps standardize temperature monitoring by eliminating the need for multiple products. The SpotOn system also helps standardize temperature monitoring, eliminating the hassle and costs associated with purchasing, stocking and managing multiple products for the same use.

3M™ Bair Hugger™ Therapy (www.bairhugger.com) Bair Hugger therapy was the first forced-air warming product line, and today it remains the market leader.

Forced-air warming therapy is a simple, safe and cost-effective method to prevent unintended hypothermia and its associated complications, which include an increased rate of wound infection,1 increased hospital length of stay2 and higher mortality rates.3 Maintaining perioperative normothermia has been cited by quality improvement initiatives around the world as a key factor in reducing the rate of surgical site infections. Many of these same initiatives include forcedair warming in their definition of active warming.

Bair Hugger warming units are used in more than 80% of U.S. hospitals, and more than 165 million patients have experienced the benefits of Bair Hugger therapy. Our ongoing commitment to innovation and patient warming has resulted in a product lineup of 25 single-use Bair Hugger warming blanket models, including five adult and two pediatric underbody series blankets.

The Bair Hugger therapy underbody series warms from underneath the patient, addressing a clinical need to prevent unintended hypothermia while providing clinicians full patient access. The full-access underbody blanket is showing rapid acceptance by the trauma community with its ability to be pre-set in the trauma bay and then warm the patient from admission and assessment to computed tomography and into the OR or ICU.

3M™ Bair Paws™ Flex Gown (www.bairpaws.com) The Bair Paws flex gown combines the best of both worlds: the comfort and convenience of the Bair Paws gown with the powerful, proven warming of Bair Hugger upper- and lower-body blankets.

With the Bair Paws flex gown, patients arrive in the OR already warm when prewarmed before surgery. The same gown enables upper- or lower-body warming in the OR thanks to effective warming tools built right into the gown. Separate upper and lower inserts allow you to activate warming where you want it, with the upper warming insert including all the features of a Bair Hugger upper body blanket.

When the patient is ready for the PACU, simply perforate off the upper body warming “sleeves,” head drape and adhesive strip to provide maximum postoperative comfort while maintaining comfort and clinical warming capabilities. The tools that helped the patient in the OR are now conveniently out of the way.

AT A GLANCE ADDRESS 3M Center, Building 275-4E-01 St. Paul, MN 55144 Phone: (800) 228-3957 Website: www.3M.com/ infectionprevention

PRODUCTS 3M™ Bair Hugger™ therapy; 3M™ Bair Paws™ patient adjustable warming system; 3M™ Ranger™ blood and fluid warming systems; 3M™ SpotOn™ temperature monitoring system

GLOBAL BUSINESS DIRECTOR, PATIENT WARMING Jay Issa

The gown’s flexibility eliminates the costs and hassles of buying, storing and using multiple items like cotton gowns and blankets, and various OR warming products while improving patient satisfaction by keeping patients warm, cozy and covered. This all-in-one warming capability makes the Bair Paws flex gown a great option for achieving normothermia-related quality measures.

3M™ Ranger™ Blood and Fluid Warming Systems (www.rangerfluidwarming.com) A complete protocol for perioperative temperature management should include both forced-air warming and the warming of infused blood and fluids to help maintain a patient’s core body temperature.

Ranger blood and fluid warming systems feature highly conductive heating plates that disperse heat immediately, handling sudden changes in flow with ease. Dry heat technology disperses heat evenly, eliminating dangerous hot spots and overheating of fluids by monitoring the temperature four times every second, automatically adjusting to maintain a consistent set point. And, because the system utilizes dry heat technology rather than a water-based method, concerns regarding water in the operating room—and its potential ties to nosocomial pathogens—are eliminated.

3M is a trademark of 3M Company, used under license in Canada.

SPOTON, BAIR HUGGER, BAIR PAWS and RANGER and the BAIR HUGGER, BAIR PAWS and RANGER logos are trademarks of Arizant Healthcare Inc., used under license in Canada.

1. Barie PS. Surgical site infections: epidemiology and prevention.

Surg Infect (Larchmt). 2002;3[supp]:S9-S21.

2. Jeran L. American Society of PeriAnesthesia Nurses Development Panel. Clinical guideline for the prevention of unplanned perioperative hypothermia. J Perianesth. Nurs. 2001;16:305-314.

3. Tryba M, Leban J. Does active warming of severely injured trauma patients influence perioperative morbidity? Anesthesiology.

1996;85:A283.

This corporate profile was reviewed and approved by Arizant Healthcare Inc., a 3M Company.

2013-2014

Corporate Profiles

ANNUAL

CADENCE PHARMACEUTICALS AT A GLANCE

C

adence Pharmaceuticals, Inc., is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.

Cadence is committed to improving the lives of hospitalized patients while building the premier hospitalfocused pharmaceutical company in North America—a vision that has remain unchanged since the company’s inception in 2004.

“Our goal is to become a leading biopharmaceutical company focused on the development and commercialization of proprietary pharmaceuticals principally for use in the hospital setting.”

—Ted Schroeder, president and CEO of Cadence

Improving the Lives of Hospitalized Patients Cadence is focused on addressing significant unmet needs in the hospital setting and the potential products that can help fill those needs to the benefit of institutions and the patients they serve. In 2006, Cadence in-licensed the exclusive U.S. and Canadian rights to OFIRMEV® (acetaminophen) injection, an intravenous formulation of acetaminophen. OFIRMEV is approved for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA granted marketing approval for OFIRMEV in November 2010, and Cadence launched the product commercially in January 2011.

Prior to the commercial launch of OFIRMEV in January 2011, the U.S. IV analgesic therapy market consisted of opioids (such as morphine, meperidine, hydromorphone and fentanyl) and two nonsteroidal anti-inflammatory drugs (NSAIDs). OFIRMEV is the first in the class of IV nonopioid, non-NSAID analgesics approved in the United States. When used as part of a multimodal approach to pain management in placebo-controlled clinical studies, OFIRMEV demonstrated significant pain relief, reduced the consumption of opioids and improved patient satisfaction.

OFIRMEV also is the first and only IV medication indicated for the treatment of pain and fever in children aged 2 years and older.

Cadence’s Hospital Sales Specialists are a team of highly experienced professionals. These field personnel have extensive hospital experience and are dedicated to educating doctors, pharmacists, nurses and other health

ADDRESS 12481 High Bluff Dr., Ste. 200 San Diego, CA 92130 Phone: (858) 436-1400 Website: www.cadencepharm.com

PRODUCT OFIRMEV® (acetaminophen) injection care professionals on effective approaches to multimodal analgesia and the appropriate use of OFIRMEV. As of March 31, 2013, an estimated 3.2-4.0 million patients have been treated with OFIRMEV, and the product was successfully placed on formulary at approximately 2,200 institutions in the United States. By bringing to market differentiated products like OFIRMEV, and establishing strong partnerships with hospitals across the nation, Cadence is striving to deliver on its mission to improve the lives of hospitalized patients.

About OFIRMEV (acetaminophen) injection OFIRMEV® (acetaminophen) injection (1000 mg/100 mL, 10 mg/mL; for intravenous use only), Cadence Pharmaceuticals’ proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever.1 The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients.1 These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain and one study evaluating OFIRMEV in the treatment of fever.1-4 The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

This corporate profile was reviewed and approved by Cadence Pharmaceuticals.

Important Safety Information OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease, or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia or severe renal impairment. Do not

EMPLOYEES 210

PRESIDENT AND CEO Ted Schroeder

exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV should be administered only as a 15-minute infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation and atelectasis in pediatric patients. OFIRMEV is approved for use in patients ≥2 years of age. The antipyretic effects of OFIRMEV may mask fever in patients with postsurgical pain.

For more information, please see the complete OFIRMEV prescribing information, available at www.OFIRMEV.com or www.cadencepharm.com.

References 1. OFIRMEV® (acetaminophen) injection prescribing information.

San Diego, CA: Cadence Pharmaceuticals, Inc. 2. Sinatra RS, Jahr JS, Reynolds LW, Viscusi ER, Groudine SB, Payen-Champenois C. Efficacy and safety of single and repeated administration of 1 gram intravenous acetaminophen injection (paracetamol) for pain management after major orthopedic surgery.

Anesthesiology. 2005;102:822-831.

3. Wininger SJ, Miller H, Minkowitz HS, et al. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery. Clin Ther. 2010; 32:2348-2369.

4. Kett DH, Breitmeyer JB, Royal MA. A randomized study of the efficacy and safety of intravenous acetaminophen vs. intravenous placebo for the treatment of fever. Clin Pharmacol Ther.

2011;90:32-39.

Anesthesiology News • August 2013

21

2013-2014

Corporate Profiles

ANNUAL

DRÄGER G Technology for Life®

AT A GLANCE

D

räger develops innovative equipment and solutions trusted by people the world over when lives are on the line. In clinical settings, industry, mining and emergency services, Dräger products protect, support and save lives.

“Technology for Life” means more than merely guaranteeing technical excellence. It means assuming responsibility for the lives of those who use our products and depend on them. Technology for Life is both our guiding principle and the central challenge that we draw on for inspiration and motivation.

“We do everything we do with passion—and we do it for life.”

—Stefan Dräger, Executive Board chairman

Global Leader in Medical Technology For more than 100 years, Dräger has been creating solutions that protect life, from innovative anesthesia delivery systems to professional diving technology and gas detection equipment. As a leader in medical and safety technology, Dräger employs more than 10,000 people worldwide. The company is present in more than 190 countries to effectively serve customers around the globe. The expertise of our management and employees is crucial to the growing globalization of our company.

Our employees are characterized by their customer focus, entrepreneurial attitude, flexibility and global orientation.

The company is headed by Stefan Dräger, the fifth generation of Dräger family members to lead the organization. Having your name on the equipment that your customers rely on makes it personal.

seamless integration of patient monitoring information enables the automated data capture that helps users focus on patients, not paperwork.

An integrated monitoring solution that makes it easier to get all the information you want It starts with an open architecture design and an ability to host multiple applications simultaneously. The widescreen format of the Infinity® Omega solution puts more of that data at your fingertips at one time. As an electronic version of the traditional patient folder, it saves you time, facilitates decision making and helps reduce the potential for medical errors. Plus, uninterrupted patient monitoring from pre-op to the postanesthesia care unit ensures the most complete patient picture possible.

Platform consistency that protects your investment and your patients Dräger’s consistency of platforms makes training more transparent, helping to minimize training costs and reduce errors. In fact, the use of a consistent user interface across Dräger anesthesia product lines can significantly reduce the time needed to learn all the platforms required to support various care settings, ranging from the operating room to magnetic resonance imaging

An integrated anesthesia solution that simplifies operation so you can focus on your patients

GLOBAL HEADQUARTERS Drägerwerk AG & Co. KGaA Moislinger Allee 53-55 23558 Lübeck, Germany Phone: +49-451-882-0 Fax: +49-451-882-2080 Email: info@draeger.com

NORTH AMERICAN HEADQUARTERS Draeger Medical, Inc. 3135 Quarry Rd. Telford, PA 18969 Phone: (800) 4-DRAGER (437-2437) Fax: (215) 723-5935 Email: info.usa@draeger.com Website: www.draeger.com

PRODUCTS Anesthesia workstations, monitoring systems, enterprise solutions, information technologies, ventilation therapy, home mechanical ventilation, warming therapy, architectural systems, accessories, surgical lighting and video systems, DrägerService®, education and training

EMPLOYEES Approximately 10,000 worldwide

PRESIDENT AND CEO Stefan Dräger

and mobile environments. More importantly, it enables a familiarity that allows you to react intuitively, confidently and efficiently.

To learn more about Dräger anesthesia workstation solutions, contact your local anesthesia sales representative or visit us on the web at www.draeger.com, or at one of the many trade shows we attend during the year.

By incorporating a single, intuitive user interface across workstations, Dräger enables anesthesia professionals to efficiently transition from one care area and case type to the next. Truly digital anesthesia delivery and

Infinity Omega-S brings together patient data from diverse sources—such as vital signs, lab data, DICOM images (x-ray, MRI, CT, US) and access to the patient’s electronic patient record (EPR). The Infinity Omega-S Solution is part of Dräger’s comprehensive anesthesia workplace.

22

Anesthesiology News • August 2013

This corporate profile was reviewed and approved by Dräger.

Dräger Anesthesia.

Rated #1 for system performance and system reliability.*

Providing clinicians the performance and reliability to meet today’s OR challenges For more than a century, Dräger has been providing anesthesia technology clinicians can count on. Our experience has led to innovations such as piston ventilation technology, which allows clinicians to deliver highly accurate therapies for improved patient outcomes. From anesthesia machines to anesthesia monitors to anesthesia information management systems, no other company is more focused on anesthesia care than Dräger.

VISIT WWW.DRAEGER.COM/PERFORM TO LEARN ABOUT OUR ANESTHESIA WORKSTATIONS *MD Buyline User Ratings, Q1 2013

2013-2014

Corporate Profiles

ANNUAL

EDWARDS W S LIFESCIENCES SC C S AT A GLANCE

A choice of hemodynamic monitoring options to meet the most challenging clinical needs.

E

dwards Lifesciences’ hemodynamic monitoring and management systems enable tailored hemodynamic optimization. The systems provide clarity into patient status, helping clinicians to make more informed and rapid decisions to achieve hemodynamic balance. Edwards’ extensive line of hemodynamic management sensors, catheters and monitoring tools support clinicians’ needs in the operating room (OR) and intensive care unit (ICU).

Hemodynamic instability may increase with more complicated or invasive procedures and with the presence of various comorbidities. As a result, clinicians’ hemodynamic monitoring needs and preferences may vary with the complexity of each procedure and patient.

Edwards provides a range of monitoring options that can be used in Perioperative Goal-Directed Therapy (PGDT) protocols to optimize fluids in moderate to high-risk surgery patients. Edwards’ objective is to provide the clarity for more informed decisions with a variety of monitoring tools that match a patient’s needs.

The ccNexfin sensor is a noninvasive finger cuff monitoring method that provides real-time hemodynamic information, including blood pressure and certain flowbased parameters such cardiac output, stroke volume and stroke volume variation.

The FloTrac sensor is the first minimally invasive hemodynamic monitoring device that connects to any existing arterial line. The FloTrac sensor continuously calculates key flow parameters such as cardiac output, stroke volume and stroke volume variation. The

ADDRESS

PreSep oximetry catheter continuously measures a patient’s central venous oxygen saturation, providing an earlier and more global view of tissue oxygenation and consumption.

The Swan-Ganz pulmonary artery catheter with advanced monitoring capability provides a single, continuous monitoring solution for the most complex patients. The Edwards Swan-Ganz catheter remains the leading pulmonary artery catheter for surgical, critical care and trauma patients worldwide.

The EV1000 clinical platform presents the physiologic and hemodynamic status of the patient in an intuitive and meaningful way. Designed to work with the FloTrac sensor and PreSep oximetry catheter, the platform offers the scalability and adaptability for both the OR and ICU. Edwards TruWave pressure transducer can be combined with the VAMP (Venous Arterial blood Management Protection) closed-loop blood sampling system to protect both patients and clinicians from the risk for infection.

Edwards offers an extensive line of education and support tools to facilitate the integration of advanced hemodynamic monitoring in all acute care settings. www.Edwards.com/CCeducation features perioperative patient simulations, simulated case studies, product animations and more. Or visit youtube.com/ECCE4you for OR- and ICU-specific playlists.

Edwards recognizes that assessing a patient’s hemodynamic and oxygenation status and minimizing the

One Edwards Way Irvine, CA 92614 Phone: (800) 424-3278; (949) 250-2500 Email: CriticalCare@Edwards.com Website: www.Edwards.com/CriticalCare Or www.Edwards.com/CCeducation

PRODUCTS Hemodynamic monitoring systems including the ccNexfin sensor; FloTrac sensor; PreSep oximetry catheter; Swan-Ganz pulmonary artery catheter; TruWave pressure transducer; VAMP (Venous Arterial blood Management Protection) system; and EV1000 clinical platform

risk for infection are fundamental requirements for moderate and high-risk surgery and for treating critically ill patients. Edwards will continue to leverage its more than 40 years of experience and leadership in this area to help clinicians advance patient care.

Caution: Federal (United States) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events.

Edwards, Edwards Lifesciences, the stylized E logo, ccNexfin, EV1000, FloTrac, Nexfin, PreSep, Swan-Ganz, TruWave and VAMP are trademarks of Edwards Lifesciences Corporation.

The EV1000 clinical platform provides a variety of informative screens from which to choose to provide immediate insight and guide your therapeutic interventions.

The platform also allows you to select the parameters most significant for your monitoring requirements, enabling you to make more informed decisions and determine the best course of action.

24

Anesthesiology News • August 2013

This corporate profile was reviewed and approved by Edwards Lifesciences.

Clarity through advanced hemodynamic monitoring for your moderate to high-risk surgery ccNexďŹ n System

FloTrac Sensor

Swan-Ganz Advanced Tech

(Noninvasive)

(Minimally-Invasive)

Plumonary Artery Catheter

##/ s 36 s 366 s 362 s #ONTINUOUS "LOOD 0RESSURE

##/ s 36 s 366 s 362

##/ s 3V/2 s 26%$6 s 26%&

A choice of hemodynamic monitoring options to meet your clinical needs %DWARDS PROVIDES A RANGE OF MONITORING OPTIONS THAT CAN BE USED IN 0ERIOPERATIVE 'OAL $IRECTED 4HERAPY 0'$4 PROTOCOLS TO HEMODYNAMICALLY OPTIMIZE YOUR MODERATE TO HIGH RISK SURGERY PATIENTS %ACH PROVIDES THE CLARITY TO MAKE MORE INFORMED DECISIONS

Visit edwards.com/PGDT to learn more about our valuable hemodynamic optimization tools and resources.

For professional use. CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events. %DWARDS ,IFESCIENCES DEVICES PLACED ON THE %UROPEAN MARKET MEETING THE ESSENTIAL REQUIREMENTS REFERRED TO IN !RTICLE OF THE -EDICAL $EVICE $IRECTIVE %%# BEAR THE #% MARKING OF CONFORMITY %DWARDS %DWARDS ,IFESCIENCES THE STYLIZED % LOGO CC.EXlN &LO4RAC .EXlN AND 3WAN 'ANZ ARE TRADEMARKS OF %DWARDS ,IFESCIENCES #ORPORATION ÂĽ %DWARDS ,IFESCIENCES #ORPORATION !LL RIGHTS RESERVED !2

Edwards Lifesciences 53! | 3WITZERLAND | Japan | China | "RAZIL | Australia | )NDIA EDWARDS COM

2013-2014

Corporate Profiles

ANNUAL

MAQUET QU MEDICAL C SSYSTEMS S S US USA The Gold Standard

M

AQUET Medical Systems USA is a market-leading medical company in the United States whose mission is to improve patient outcomes and quality of life through advanced technology. MAQUET designs, develops and distributes innovative products and therapeutic solutions, and provides infrastructure capabilities for the hybrid operating room (OR), general OR, intensive care unit (ICU) and patient transport within acute care hospitals.

MAQUET has a long history of innovation in anesthesia, beginning with the introduction of its first anesthesia machine in 1981. Since then, the company has delivered more than 6,500 units to hospitals worldwide. It also has set market standards with its high-performance SERVO ventilation platform for more than 40 years. The company has a deep understanding of mechanical ventilation and the challenges facing anesthesiologists today.

Not only are patient demographics constantly shifting, but surgical procedures are becoming more complex on a daily basis, necessitating advanced technology to ensure optimal patient care. MAQUET invests significantly in research and development to meet the changing needs of hospitals and anesthesiologists and ensure that it can provide anesthesia products that offer high-performance ventilation and support capabilities. MAQUET’s flagship anesthesia product, the FLOW-i Anesthesia Delivery System with high-performance SERVO ventilation, offers true ICU ventilator performance and effective anesthesia delivery from the same unit.

FLOW-i Anesthesia Delivery System With High-Performance SERVO Ventilation MAQUET’s FLOW-i Anesthesia Delivery System seamlessly combines high-performance SERVO ventilation with precise anesthesia delivery to help meet the needs of all patients. These include the most challenging cases, such as obese patients with high abdominal and

AT A GLANCE thoracic pressures, older patients suffering from multiple medical conditions, the critically ill and the smallest neonates. FLOW-i reacts quickly to changing parameters as the low internal system volume enables rapid changes in gas concentration when needed, and facilitates fast wash-in and wash-out of the anesthetic agent.

This process helps to minimize waste and unnecessary use of the agent through precise delivery technology.

High-Performance Ventilation Features • Set tidal volume is accurately delivered even under high abdominal and thoracic pressures, helping to avoid hypoventilation.

• Fast rise time and high flow rates adapt to varying inspiratory demand in the presence of increasing airway pressure.

• Sensitive triggering improves synchrony in pediatric patients and those with decreased respiratory drive.

• Consistent and accurate PEEP levels are maintained.

• Controlled pressure drop during expiration decreases expiratory resistance and work of breathing, in addition to minimizing auto-PEEP at higher respiratory rates.

Advanced Design and Technology The FLOW-i system’s ergonomically designed, fully electronic platform and touch-screen interface are easy to use and upgrade for enhanced workflow today and in the future. The open architecture allows hospitals to add the patient monitor and data management system of their choice and easily integrate future software and hardware advances into the system—increasing cost efficiency by avoiding the need for costly equipment replacement or upgrades. In addition, clinician ease of use and comfort are engineered into every FLOW-i machine with its height adjustability, movable arms and integrated table light.

U.S. HEADQUARTERS MAQUET Medical Systems USA 45 Barbour Pond Dr. Wayne, NJ 07470 Phone: (888) 627-8383 Website: www.maquetusa.com

PRODUCTS Intensive care ventilators and anesthesia machines, suite of cardiovascular products (for intra-aortic balloon counterpulsation, cardiac assist, coronary artery bypass surgery, aortic and peripheral vascular surgery, and extracorporeal circulation), flexible room design for OR and ICU, OR tables, lights and ceiling supply units and OR integration

EMPLOYEES 6,000 MAQUET employees in 50 international sales and service organizations, as well as a network of more than 280 sales representatives

PRESIDENT AND CEO Raoul Quintero

Innovative Volume Reflector™ Re-Breathing Technology The FLOW-i system features the innovative Volume Reflector technology to ensure that the breathing circuit will never be empty and ventilation will remain uninterrupted regardless of surgical constraints, changing conditions or patient position. The re-breathing technology consists of a rigid reservoir to minimize internal system volume for high ventilation performance. It replaces both the traditional bag-in-bottle (bellows) and the piston, allowing the partial re-administration of rebreathed gas to the patient via the circle system. Oxygen-driven by design, the Volume Reflector helps to minimize the risk for delivering a potentially dangerous hypoxic mixture in the presence of leaks during lowflow anesthesia. FLOW-i also contains anesthetic agent injection vaporizers that are fully electronic, are lightweight and can be refilled while slotted in the machine, even when one is still in use.

Learn More To learn more about the MAQUET FLOW-i Anesthesia Delivery System, please visit www.maquetusa.com.

26

Anesthesiology News • August 2013

This corporate profile was reviewed and approved by MAQUET Medical Systems USA.

-!1 #OPYRIGHT¬-!15%4¬-E EDICAL¬3YSTEMS¬53!¬OR¬ITS¬AFFILIATES ¬s¬ #!54)/. ¬&EDERAL 53 ¬LAW¬RESTRICTS¬THIS¬DEVICE¬TO¬SALE¬BY¬OR¬O EN¬THE¬ORDER¬OF¬A PHYSICIAN ¬2EFER¬TO)NSTRUCTIONS¬FOR¬5SE¬FOR¬CURRENT¬INDICATIONS ¬WARNINGS ¬CONTRAI TRA NDICATIONS ¬AND¬PRE ECAUTIONS

FLOW-i A REVOLUTION IN ANESTHESIA DELIVERY TECHNOLOGY

Anesthesia Delivery And The True Cost Of Ownership )N¬TODAY S¬EVER CHANGING¬HEALTHCARE¬REIMBURSEMENT¬ENVIRONMENT ¬HOSPITALS¬AND¬OUTPATIENTSURGERY¬CENTERS¬DEMAND¬SUPERIOR¬TECHNOLOGY¬WITH¬LONG TERM¬COST¬CONTAINMENT ¬0ARTNER¬WITH-!15%4¬AND¬DISCOVER¬THE¬TRUE¬COST¬OF¬YOUR¬CURRENT¬ANESTHESIA¬PLATFORM ¬COMPARED¬TO¬THEREVOLUTIONARY¬&,/7 I¬SYSTEM ¬AND¬MAKE¬THE¬RIGHT¬CHOICE¬FOR¬YOUR¬PATIENTS¬AND¬YOUR¬BUSINESS Call us at 888-627-8383 or email marketing@maquet.com to trial the revolution in anesthesia delivery technology — FLOW-i.

Learn More maquetflowi.com

www.maquetusa.com

2013-2014

Corporate Profiles

ANNUAL

MASIMO AT A GLANCE

Taking Noninvasive Monitoring to New Sites and Applications

F

or more than 20 years, Masimo has focused on a singular mission—helping clinicians improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications.

Continuing to SET the Benchmark for Oxygenation Monitoring During Challenging Conditions Masimo SET® (Signal Extraction Technology®) is the proven leader in pulse oximetry, demonstrated by both clinical research and the real-world success of customers and OEM partners. More than 100 independent and objective studies have shown that Masimo SET® outperforms all other pulse oximetry technologies, providing clinicians with unmatched sensitivity and specificity to make critical patient care decisions—even under the challenging conditions of motion and low perfusion.1 Most importantly, only Masimo SET® pulse oximetry has been shown to improve patient outcomes by helping clinicians reduce retinopathy of prematurity2; screen newborns for critical congenital heart disease (CCHD)3,4; reduce ventilator weaning time5; and save lives while reducing rapid response activations and ICU transfers on the general floor.6

rainbow® Technology Helps Clinicians Protect Patients From Hidden Dangers Throughout the Hospital rainbow® technology comprises a suite of continuous, noninvasive measurements designed to help clinicians with some of the most common, costly and critical decisions made in health care today. The rainbow® suite includes: • Total hemoglobin (SpHb®) • Methemoglobin (SpMet®) • Carboxyhemoglobin (SpCO®) • Oxygen content (SpOC™) • Acoustic respiration rate (RRa™) • All Masimo SET® measurements

Helping Clinicians Reduce Blood Transfusions and Detect Internal Bleeding

hospitals,7 a growing body of clinical evidence suggests that overuse of RBC transfusion increases both patient risk and the cost of care.8-11 Masimo’s continuous, noninvasive SpHb monitoring helps clinicians reduce RBC transfusions in low blood loss surgery12 and high blood loss surgery.13 In addition, by measuring continuously, SpHb helps clinicians detect real-time drops in hemoglobin that may be indicative of bleeding. Identification of low or falling hemoglobin levels could allow interventions that may prevent unnecessary disability or death.

Protecting More Patients by Monitoring Every Breath The Anesthesia Patient Safety Foundation and the Joint Commission recommend continuous oxygenation and ventilation monitoring in all patients receiving opioid-based pain medications.14 However, current methods for respiration rate monitoring are limited by patient tolerance. While we offer the best-in-class capnography solution, we believe rainbow Acoustic Monitoring™ with Acoustic Respiration Rate (RRa) is better suited for postsurgical monitoring and conscious sedation due to its demonstrated ability to detect respiratory pause.15

References 1. Shah N, Ragaswamy HB, Govindugari K, Estanol L. J Clin Anesth.

2012:24:385-391.

2. Castillo A, Deulofeut R, Critz A, Sola A. Prevention of retinopathy of prematurity in preterm infants through changes in clinical practice and SpO2 technology. Acta Paediatr. 2011;100:188-192.

3. de-Wahl Granelli A, Wennergren M, Sandberg K, et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;338: a3037. ®

features complete rainbow® measurements, intuitive touchscreen display, standard wireless radio, and full-screen trending.

28

Anesthesiology News • August 2013

4. Ewer AK, Lancet. 2011;378:785-794.

PRODUCTS Masimo SET® pulse oximetry and sensors; rainbow® Pulse CO-Oximetry and sensors; rainbow Acoustic Monitoring™; SedLine® brain function monitoring; Phasein™ capnography and gas monitoring; Patient SafetyNet™ general floor monitoring

MISSION STATEMENT Improving patient outcomes and reducing cost of care by taking noninvasive monitoring to new sites and applications

EMPLOYEES 3,000

Joe Kiani

In August 2012, the Joint Commission Sentinel Event Alert on the safe use of opioids in hospitals recommended implementation of better dosing along with continuous oxygenation and ventilation monitoring (instead of spot checks) in postsurgical patients.16 Our Patient SafetyNet system combines Masimo SET® pulse oximetry, breakthrough rainbow® measurements and remote patient monitoring with wireless clinician alerts. After implementing Masimo SET® and Patient SafetyNet in a postsurgical floor where only intermittent spot checking was used before, Dartmouth-Hitchcock Medical Center reduced rapid response activations by 65% and ICU transfers by 48%6 and saved $1.48 million annually. In addition, no patients suffered irreversible, severe brain damage or died as a result of respiratory depression from opioids over a five-year period.17

*The use of the trademarks PATIENT SAFETYNET and PSN is under license from University Health System Consortium.

40 Parker Irvine, CA 92618 Phone: (949) 297-7000 Website: www.masimo.com

FOUNDER AND CEO

Helping Improve Outcomes on the General Floor With Patient SafetyNet™*

Although red blood cell (RBC) transfusion is one of the most frequent procedures performed in U.S.

ADDRESS

5. Durbin CG Jr, Rostow SK. More reliable oximetry reduces the frequency of arterial blood gas analyses and hastens oxygen weaning after cardiac surgery: a prospective, randomized trial of the clinical impact of a new technology. Crit Care Med. 2002;30:1735-1740.

6. Taenzer AH, Pyke JB, McGrath SP, Blike GT. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology.

2010;112:282-287.

7. AHRQ. Inpatient Sample. 1997-2007.

8. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med. 2008;36:2667-2674.

9. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion.

Cochrane Database Syst Rev. 2012;4:CD002042.

10. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion. 2010;50:753-765.

11. Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation.

2007;116:2544-2552.

12. Ehrenfeld JM et al. ASA. 2010. LB05 (abstract).

13. Awada WFN, Maher F. Proceeding of the Society for Technology in Anesthesia Annual Meeting, 2013: p 51.

14. Stoelting RK et al. APSF Newsletter. 2011. www.apsf.org.

15. Ramsay MA, Usman M, Lagow E, et al. The accuracy, precision and reliability of measuring ventilatory rate and detecting ventilatory pause by Rainbow Acoustic Monitoring and Capnometry. Anesth Analg. 2013 April 30. [Epub ahead of print] 16. The Joint Commission. Sentinel Event Alert. 2012:49.

17. Taenzer AH, et al. APSF Newsletter. 2012;27:1.

This corporate profile was reviewed and approved by Masimo.

Breakthrough Measurements.

Radical Monitor.

Radical-7

®

Once again raising the technology bar, the Radical-7 leverages Masimo’s breakthrough noninvasive measurements with a radical departure from traditional monitoring for breakthrough functionality designed to automate the process of care and enable clinicians to instantly adapt to changing monitoring needs in individual patients and care areas. > Breakthrough noninvasive measurements: · Total Hemoglobin (SpHb®) · Pleth Variability Index (PVI®) · Oxygen Content (SpOC™) · Acoustic Respiration Rate (RRa™) ® · Methemoglobin (SpMet ) · Carboxyhemoglobin (SpCO®) > Instantly adaptable functionality > Intuitive touchscreen operation > Integrated wireless connectivity > Easy customization

For more information, visit www.masimo.com/rainbow/radical7.htm 800-257-3810 © 2013 Masimo Corporation. All rights reserved.

2013-2014

Corporate Profiles

ANNUAL

MCMAHON PUBLISHING

M

cMahon Publishing was founded in 1972

by Raymond E. McMahon and has grown to become one of the nation’s largest family-owned medical publishers.

McMahon publishes a broad array of medical newsmagazines in various specialties, including anesthesiology, gastroenterology, general surgery, hospital and specialty pharmacy, infectious diseases, pain medicine, rheumatology and oncology. The combined circulation of McMahon publications is approximately 300,000 doctors and pharmacists.

McMahon newsmagazines are accompanied by a full line of digital media, including websites, e-newsletters, digital editions, podcasts, Twitter feeds, Facebook pages and other digital communication to readers.

Foremost among McMahon publications is Anesthesiology News. Now in its 39th year, Anesthesiology News has been the best-read publication in the field for the past 16 years (according to Kantar Media). Nearly 93% of the 46,546 U.S.-based anesthesiologists read this publication each month.

AT A GLANCE ADDRESS 545 W. 45th St., 8th Fl. New York, NY 10036 Phone: (212) 957-5300 Fax: (212) 957-7230 Websites: www.mcmahonmed.com www.anesthesiologynews.com @anesthesianews anesthesiologynews

PRODUCTS Medical newsmagazines, custom medical publications, educational reviews, special editions, podcasts, pocket guides and more.

EMPLOYEES 60

PUBLISHER, CEO AND MANAGING PARTNER Raymond E. McMahon

GENERAL MANAGER, PARTNER Matthew McMahon

ANESTHESIOLOGY NEWS Managing Editor Adam Marcus Senior Group Publication Director Richard Tuorto Manager, Publication Sales Angela Labrozzi Junior Sales Associate, Classifieds Alina Dasgupta Production Manager Martin Barbieri Art Director Blake Dennis

30

Anesthesiology News • August 2013

This corporate profile was reviewed and approved by McMahon Publishing.

2013-2014

Corporate Profiles

ANNUAL

PACIRA C PHARMACEUTICALS, C U C S, INC. C

P

acira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products to address the needs of acute care practitioners and their patients. Pacira is driven by a dynamic workforce committed to optimizing patient care and satisfaction in the acute care setting, with a special focus on improving outcomes in postsurgical pain management.

A Proprietary Drug Delivery Platform The cornerstone of the Pacira product portfolio is DepoFoam®, a proprietary drug delivery platform designed to extend a medication’s duration of action without altering its molecular structure. The DepoFoam carrier matrix is made up of multivesicular liposomes that encapsulate a drug. Each chamber is separated by lipid membranes that naturally erode to release the drug over a desired period of time.

EXPAREL as the foundation of an opioid-sparing multimodal postsurgical pain management regimen. Recently published national and regional retrospective analyses2,3 of more than 400,000 postsurgical patients receiving opioids concluded that patients who experienced opioid-related adverse events had both longer lengths of hospital stay and higher hospitalization costs. The company’s efforts are buoyed by a groundswell movement led by governmental and independent health care organizations to mitigate potentially fatal side effects related to the use of opioids by recommending a shift toward opioid-sparing pain regimens, especially in high-risk postsurgical patients.

Clinical Utility Across a Broad Range of Potential Applications EXPAREL has broad applications across multiple surgical specialties, as well as in the anesthesiology arena.

Pacira recently presented data supporting the administration of EXPAREL via infiltration into the transversus abdominis plane to produce up to 72 hours of postsurgical analgesia. The company is also advancing its Phase 3 nerve block program studying the safety and efficacy of EXPAREL administered as a femoral or intercostal nerve block.

The Pacira Advantage

A First of Its Kind Single-Dose Local Analgesic In 2012, Pacira successfully launched EXPAREL® (bupivacaine liposome injectable suspension), the first and only DepoFoam-based local analgesic. Indicated for administration into the surgical site to produce postsurgical analgesia, a single dose of EXPAREL provides nonopioid pain control with reduced opioid requirements for up to 72 hours* without the need for catheters or pumps.1

Shifting the Postsurgical Pain Management Paradigm The launch of EXPAREL is bolstered by a robust Phase 4 clinical program, which builds a compelling case for

Discovery, innovation and proprietary expertise are the hallmarks of the Pacira competitive advantage. The company not only holds the exclusive rights and expertise to DepoFoam, but owns the unique distinction of being the only company in the world with the ability to manufacture DepoFoam-based products, such as EXPAREL, on a large commercial scale.

With steadily increasing demand and a growing list of potential clinical applications, Pacira and EXPAREL are poised to become vital fixtures in the postsurgical pain management arena.

For more information about Pacira Pharmaceuticals Inc., visit www.pacira.com.

Important Safety Information for EXPAREL EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if

This corporate profile was reviewed and approved by Pacira Pharmaceuticals, Inc.

AT A GLANCE ADDRESS 5 Sylvan Way Parsippany, NJ 07054 Phone: (973) 254-3560 Fax: (973) 267-0060 Website: www.Pacira.com For more information on EXPAREL, visit www.EXPAREL.com For medical inquiries related to EXPAREL, contact Medical Information at medinfo@pacira.com or 1-855-RX-EXPAREL (1-855-793-9727)

administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs, should occur during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk for developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence ≥10%) following the administration of EXPAREL were nausea, constipation and vomiting. *Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy and hemorrhoidectomy procedures.

1. Gorfine SR, Onel E, Patou G, Krivokapic ZV. Dis Colon Rectum. 2011;54:1552-1559.

2. Oderda GM, Gan TJ, Johnson BH, Robinson SB. J Pain Palliat Care Pharmacother. 2013;27:62-70.

3. Kessler ER, Shah M, Gruschkus SK, Raju A. Pharmacotherapy. 2013;33:383-391.

HO-13E004

Anesthesiology News • August 2013

31

2013-2014

Corporate Profiles

ANNUAL

PLEXUS INFORMATION SYSTEMS, INC. AT A GLANCE

A Plexus Management Group Subsidiary

P

lexus Management Group, Inc. (“Plexus”) is a practice management organization dedicated to serving anesthesia and pain management providers. Plexus provides effective solutions to maximize practice operations and return for each of its clients.

Among the services Plexus offers are: • Payer contract negotiation • Strategic planning and budgeting • Hospital/Ambulatory Surgery Center negotiations • Billing and collections • Anesthesia department consulting • Human resources and benefits management • Credentialing • Quality assurance/risk management services • Compliance support • Information technology assessment • Captive insurance development • Joint Commission preparation • Certified coding • OR management In 2009, after researching anesthesia information management systems (AIMS) for their clients, the executive team at Plexus agreed the best solution was to develop their own AIMS. Albert Woo, MD, president and founder of Plexus Information Systems, Inc. (“Plexus IS”) designed the first AIMS for the Apple iPad iOS platform. Dr. Woo is a board-certified anesthesiologist with vast experience in health care information technologies (IT). He began studying IT during his undergraduate studies in molecular cell biology at the University of California, Berkeley, and worked for several software companies before and during his medical studies at New York Medical College. Dr. Woo’s clinical and software development background is unique in the industry and proved the ideal combination to design one of the most innovative AIMS on the market today.

Anesthesia Touch™—The Ultimate AIMS The Plexus IS intraoperative anesthesia record, Anesthesia Touch™, offers the most functionality and adaptability of any AIMS and uses a cloud-based solution for capturing, managing and storing patient information.

Anesthesia Touch is a full-featured AIMS that operates natively on the iPad iOS platform, as well as traditional desktop workstations. Anesthesia Touch gives anesthesia providers the power to manage information electronically from single providers to the largest integrated delivery networks on one simple interface from multiple platforms and locations. Plexus IS makes use of patient registration, operating room scheduling, lab and pharmacy systems integration to achieve unparalleled clinical decision support and reporting. Plexus IS offers complete client support and maintenance, which can significantly decrease costs for health care facilities.

32

Anesthesiology News • August 2013

Plexus IS understands that each individual anesthesia provider has preferences in his or her own practice. Anesthesia Touch provides custom templates that adapt to the complexity of medical procedures and offer the users efficient means for record keeping. In addition to using automated documentation of physiologic and machine data, Anesthesia Touch provides intelligent clinical decision support such as allergy alerts, antibiotic re-dosing and best-practice compliance reminders.

Anesthesia Touch attained a “Completed EHR [electronic health record] Certification for Complete EHR Ambulatory” by the Drummond Group in 2012; it therefore will qualify anesthesia groups under Meaningful Use.

PLEXUS INFORMATION SYSTEMS CORPORATION A privately held company providing the most comprehensive AIMS on the market today that operates on the Apple iPad iOS platform.

PRODUCT Anesthesia Touch™ gives anesthesia providers the power to manage information electronically in the perioperative environment on one simple interface from multiple locations.

FOUNDER AND PRESIDENT Albert Woo, MD

Quality Reporting The Plexus IS reporting engine also allows departments and facilities to harvest valuable information for analysis. Anesthesia Touch has extensive quality data-capture features built into the system. Plexus IS can help practices design their own data-capture systems in addition to helping them participate in national quality databases such as the Anesthesia Quality Institute and the Society for Ambulatory Anesthesia’s Clinical Outcome Registry.

This type of quality reporting can be used to help improve clinical practice as well as benchmarking performance.

Meaningful Use Plexus IS has incorporated all the criteria defined by CMS and fit them into an AIMS. Anesthesia providers can now take advantage of the interoperability encouraged

by Meaningful Use in helping improve patient care and decreasing health care costs.

Plexus IS Innovations • 1st AIMS on the iPad iOS Platform • 1st AIMS to obtain ONC-ATCB Complete Ambulatory EHR Certification • 1st AIMS to obtain Vital Signs from the iPad Platform • 1st AIMS to feature Simultaneous Charting Access

CONTACT INFORMATION Phone: (800) 247-5013 Email: info@plexusis.com Website: www.plexusis.com LinkedIn: company/ plexus-information-systems PARENT COMPANY Plexus Management Group, Inc. Bob McIvor, President Dan Reale, Executive Vice President Phone: (781) 407-7771 Email: info@plexusmg.com Website: www.plexusmg.com

Health care is about providing quality care. Yet, for many health care professionals, the responsibilities of running a profitable business get in the way of this allimportant mission. At Plexus, the goal is to become your business partner, providing effective, lasting solutions to your most complex business issues. Plexus offers consulting and management services to physician practices, hospitals and medical groups. Plexus’ experienced business and clinical management teams ensure that business-related functions run at maximum efficiency.

Solutions for Busy Anesthesiologists We Don’t Practice Management.

We Manage PracticesSM Plexus is one of the largest private managers of anesthesia services (more than 600 anesthesia professionals under management) with anesthesia clients throughout the United States. Plexus top management has more than 175 years combined health care expertise with more than 100 years of direct anesthesia management.

Every challenge is different. Naturally, so are the solutions. Plexus will work with you to find those that meet your specific financial, strategic and/or operational needs. In everything Plexus does, risk management and patient safety are of the utmost importance—evidenced in groundbreaking offerings like the captive insurance programs developed for a large client. Similarly, the development of Plexus Information Systems sets Plexus apart as a leader in anesthesia practice management.

This corporate profile was reviewed and approved by Plexus Information Systems, Inc.

THE ULTIMATE ANESTHESIA INFORMATION MANAGEMENT SYSTEM Discover the Power of Anesthesia TouchTM Plexus Information Systems, Inc. (Plexus IS), a subsidiary of Plexus Management Group, Inc., presents Anesthesia Touch™, a functionally rich AIMS that offers the most adaptability and scalability in the industry.

Anesthesia Touch is the only AIMS solution to offer direct integration with all EMRs in the U.S.A. Anesthesia Touch gives anesthesia providers the power to manage information electronically from single providers to the largest IDNs on one simple interface from multiple platforms and locations.

Apple iOS and Windows Touchscreen

Real-time Decision Support

Comprehensive Medication Safety System with Integrated Single Login

800.247.5013

Disease Comorbidity Capture

Operates Natively on iPad

Cloud-based Solution

Full Discrete Data Interface

AQI and SCOR Preferred Vendor

OR Efficiency and Utilization

Automated Data Capture

Pharmacy Cost and Usage

Full EHR Meaningful Use Certified

Simultaneous Record Access

info@plexusis.com

www.plexusis.com

2013-2014

Corporate Profiles

ANNUAL

SSPACELABS C S HEALTHCARE C

S

pacelabs Healthcare is a comprehensive, perioperative solutions provider developing, manufacturing and distributing medical equipment and services throughout the world. We provide solutions for patient monitoring and connectivity, anesthesia delivery and ventilation, diagnostic cardiology and supplies and accessories, selling to hospitals, clinics and physician offices. Spacelabs’ world headquarters, in Snoqualmie, Wash., is where we develop and manufacture anesthesia, patient monitoring and cardiology products.

Spacelabs provides various perioperative solutions from low to high acuity, covering simple to complex cases and pediatric to geriatric patients—offering you the choices you need in anesthesia delivery, patient monitoring and supplies and accessories. What’s more, you can configure solutions to satisfy your individual practices and preferences. Our product line is continually developing and expanding with some exciting new additions coming in the near future.

Spacelabs Healthcare has more than 50 years of innovation and service and began as the innovator of life support systems for the Gemini and Apollo space missions. Always endeavoring to meet our customers’ unmet needs, the result is the complete rethinking of the anesthesia delivery system experience.

Welcome to ARKON Until today, anesthesia delivery systems were designed with functionality and reliability as the priority. While important, we saw these as our starting point.

ARKON™ is our “evolutionary” new anesthesia delivery system that pushes the boundaries to provide advanced flexibility and ergonomics for you, the people who use these machines.

ARKON puts your patient front and center—offering anesthesiologists the maximum in functionality, comfort and control. Through a combination of an expandable clinical console, which extends out to enable a wide-angle view of your clinical setting, and enhancements not previously available in the perioperative environment, we focused ARKON on you, so you can focus on your patient. While other machines concentrate on the technology of anesthesia delivery, we believe you will find ARKON unique in its attention to the details of how you work. Providing you with an improved workplace is our priority, with flexibility our focus. Designed to improve the user experience, ARKON is part of our mission to inspire the world to bring the best care to patients as well as their families.

Spacelabs Healthcare is dedicated to developing and supporting those tools.

Spacelabs Healthcare Collaborates With Clinicians To Provide Clinically Relevant Products Spacelabs Healthcare values the strong clinical partnerships that we have developed and maintained over the past half-century. Through continuous and effective communication with clinical user groups, we gather a deep understanding of needs and requirements in order to develop solutions to help clinicians achieve their goals.

Always a leader in innovation with accessibility, continuity and partnership, Spacelabs Healthcare delivers on our promises to: • Help improve patient care.

• Help clinicians achieve their goals.

• Demonstrate honesty, reliability and integrity.

• Deliver quality products and service, service, service.

Excellence in Customer Service and Support

AT A GLANCE ADDRESS 35301 SE Center St. Snoqualmie, WA 98065 Phone: (425) 396-3300 Website: www.spacelabshealthcare.com Email: marketing@spacelabs.com

PRESIDENT AND CEO Nicholas Ong

When selecting a perioperative solutions company, consider Spacelabs’ experience and heritage of innovative and intuitive products developed in partnership with our customers to address real-life clinical needs.

Our customer-first philosophy reflects our commitment to superior care for you and your patients as well as product support by our award-winning service team.

At Spacelabs Healthcare, excellence in customer service and support are not just words; they are values, embraced by all our employees, that shape the way that we do business. As a result, IMV ServiceTrak™, one of the most respected surveys in the health care industry, ranked Spacelabs “Best for Overall Service Performance among Industry Peers” in 2011 for the second consecutive year, and three of the last six years.

We work cooperatively to develop long-term relationships with our suppliers, our distribution partners and our customers to provide the products, tools and services you need. Spacelabs is a focused, agile organization that is here to serve health care professionals worldwide. Our goal is to provide our customers more time to care. Customer loyalty is our reward.

“The Spacelabs Advantage” For more than 50 years, health care professionals have experienced the company’s proven commitment to connecting innovation with care; stability for a strong future; collaboration with clinical and technological partners; effective implementation of real-world solutions; and service wherever, whenever and however it’s needed. The most important factor in patient care is a knowledgeable medical professional with the right tools.

34

Anesthesiology News • August 2013

This corporate profile was reviewed and approved by Spacelabs Healthcare.

ASA Booth #1326

2013-2014

Corporate Profiles

ANNUAL

TEAMHEALTH ANESTHESIA S S

T

eamHealth Anesthesia is a nationally recognized provider of comprehensive anesthesia, pain management and administrative services for hospitals, surgery centers and pain management clinics. Our proven anesthesia service platform has been specifically designed to maximize operating room (OR) performance while increasing patient and surgeon satisfaction.

With extensive experience as anesthesia providers, business managers and hospital/medical staff leaders, our leadership team is unsurpassed. After more than a decade of experience in dozens of hospitals nationwide, we have helped a broad range of health care facilities improve the performance of their anesthesia departments.

Whether it’s augmenting an existing anesthesia group or forming a new one, TeamHealth Anesthesia provides customized solutions and first-rate specialists. In fact, we are anesthesia industry leaders in: • • • • • • • •

Surgeon satisfaction Quality metrics measurement and reporting Patient safety Recruitment and retention of anesthesiologists and certified registered nurse anesthetists (CRNAs) OR efficiency High-throughput surgery environments Group management and leadership Billing, collections, credentialing

Your Career Will Thrive With TeamHealth Anesthesia Founded by anesthesiologists, TeamHealth Anesthesia uniquely understands the needs and expectations of anesthesiologists and CRNAs. Our solid reputation in the provider community allows us to partner with the best anesthesia clinicians in the market, creating stable, top-notch groups for our hospital and surgeon partners.

To continue our success, we need leading clinicians like you to be part of our team.

medical centers and teaching facilities in urban areas.

With a wide variety of practice environments and case mixes, as well as varying anesthesia delivery models— from direct anesthesia care to anesthesia care teams— you’ll find opportunities to: • Nurture your professional interests while advancing your career • Receive a highly competitive salary along with benefits and performance incentives • Choose from coast-to-coast nationwide practice opportunities • Practice medicine without the daily burdens of managing a practice • Focus on what matters most to you: patient care Best of all, when you’re part of the “team,” we provide unparalleled resources that will help you be one of the best anesthesia professionals in the nation. Through timely risk management and our leadership skills education programs like LEAD™, the TeamHealth Leadership Development Institute™ and others, you will discover that we care as much about your career and quality of life as you do.

Anesthesia Care Team Anesthesia programs nationwide are moving from the physician-only anesthesia service delivery models to mixed care team models that are comprised of physicians and CRNAs. TeamHealth Anesthesia has extensive experience in the anesthesia care team (ACT) model and has performed multiple successful transitions from physician-only models to ACT models. Our experience has shown us that the benefits of the ACT model include improved practice efficiencies, increased revenue and profits, standardization of care, flexibility, and increased patient and surgeon satisfaction.

Always sensitive to the needs of surgeons and the hospitals we serve, TeamHealth Anesthesia implements the following transition activities with minimal disruption to the existing anesthesia program:

Coast-to-Coast Opportunities Your perfect practice is waiting for you at TeamHealth Anesthesia. We have practices throughout the United States, so whether you’re looking for cities, suburbs, mountains or beaches, we have the practice you want, where you want, just waiting for you to make it your own. Our partner hospitals range from community hospitals in comfortable bedroom townships to major

36

Anesthesiology News • August 2013

• Recruit anesthesia medical directors who possess a strong customer service mindset, support their respective hospital’s vision and goals, communicate with surgeons to ensure mutual understanding of the ACT model to be implemented, have experience working with CRNAs and create positive group cultures.

AT A GLANCE ADDRESS 7111 Fairway Dr. Ste. 450 Palm Beach Gardens, FL 33418 Phone: (877) 799-3552 Email: anesthesiajobs@teamhealth.com Website: www.teamhealth.com

SERVICES TeamHealth Anesthesia is one of the nation’s leading outsourced anesthesia and pain management service organizations. Specializing in delivering high-quality, cost-effective and servicefocused patient care.

• Recruit and retain a core group of physicians and CRNAs. • Provide team-building workshops with anesthesia providers, surgical leadership and the hospital executive team.

• Appoint an internal chief CRNA to help physicians and CRNAs work as a team.

• Leverage TeamHealth’s national customer service training programs to improve satisfaction scores.

• Implement daily anesthesia “team huddles” to ensure all processes are properly in place for surgeries and patients scheduled for the next day.

By implementing the ACT model, our client hospitals are seeing faster room turnovers as well as drastically improved efficiency and reduced costs.

The right job. The right place.

The right partner.

TeamHealth Anesthesia is one of the nation’s leading outsourced anesthesia and pain management service organizations. Specializing in delivering high-quality, cost-effective and service-focused patient care, our services are designed to maximize OR performance while increasing patient and surgeon satisfaction.

For more information, visit us online at www. teamhealth.com, call (877) 799-3552 or email anesthesiajobs@teamhealth.com.

This corporate profile was reviewed and approved by TeamHealth Anesthesia.

Advance Your Anesthesia Career TeamHealth Anesthesia has ideal practices for anesthesiologists and CRNAs all across the country.

Our team-oriented approach stresses service and quality patient outcomes in professional practice environments. If you’re looking for an attractive income and beneďŹ ts package, performance incentives, a variety of practice choices and career advancement, then visit teamhealth.com today.

The right job. The right place. The right partner.

www.teamhealth.com 877.799.3552 | anesthesiajobs@teamhealth.com

2013-2014

Corporate Profiles

ANNUAL

TELEFLEX

T

eleflex, through its Arrow®, Hudson RCI®, LMA® and Rusch® branded products, is dedicated to reducing complications and cost, protecting patients and caregivers, and improving patient outcomes with products that span the continuum of anesthesia—from the operating room to the recovery room, to critical care and beyond.

We consult with clinicians and design our products to address modern clinical challenges, striving to help providers adapt to an ever-changing global health care environment.

LMA Airway Management™— LMA Better by Design® Teleflex is proud to welcome the LMA® brand into our portfolio of airway management solutions.

LMA airways have a proven track record of safety and efficacy, building on a 20-year history of innovation and trust. The subject of more than 3,000 clinical references, each LMA airway has been carefully designed and tested to meet exacting standards. LMA airways are included in the American Heart Association Guidelines for Resuscitation and the American Society of Anesthesiologists Difficult Airway Algorithm.

The LMA Supreme® single-use airway combines the best features of all previous LMA airways and is designed for safety and ease of use. Whether for a routine procedure or to manage a higher-risk patient, it is designed to channel fluids away from the airway in the unlikely event of active or passive regurgitation and allows for diagnostic testing and verifiable positioning.

The Next Generation in One-Lung Ventilation

The Rusch® EZ-Blocker™ endobronchial blocker is the next generation in one-lung ventilation, designed to enhance patient outcomes during selective procedures.

Developed by an anesthesiologist for use by anesthesiologists to provide an improved device for lung isolation, the EZ-Blocker endobronchial device has a unique Y-shaped distal end that mirrors the bifurcation of the trachea. This unique end allows for the intuitive placement of the cuffs in the right or left bronchus. Once the EZ-Blocker endobronchial device is advanced through the distal end of a single-lumen endotracheal tube, the bifurcated cuffs separate and are naturally directed into the left and right main stem bronchi.

38

Anesthesiology News • August 2013

The EZ-Blocker endobronchial device can be securely placed at the carina without the need for navigation of the cuff into either of the bronchi.1 With the EZ-Blocker endobronchial device, cuff inflation can be performed just before lung isolation, which minimizes the need to manipulate the catheter after placement and reduces the potential for the cuffs to become dislodged.

Needle-Free Solutions for Drug Delivery The LMA Atomization ® family of products provides a simple-to-use, needle-free solution for use with drugs approved for intranasal and oropharyngeal delivery. The LMA® MAD Nasal™ intranasal nucosal atomization device is the safe and painless way to deliver medication with rapid adsorption/transport across mucosal membranes to the bloodstream. The LMA® MADgic Airway™ intubating airway with mucosal atomization and oxygen delivery is the most innovative choice to create a temporary airway to facilitate fiber-optic intubation, combining atomized topical anesthetic and oxygen delivery in an innovative and elegantly designed oral airway. The LMA® MADgic® laryngo-tracheal mucosal atomization device is the most versatile choice to administer medication across the entire upper airway and beyond the vocal cords.

Post-Op Pain Management Solutions The Arrow® FlexBlock® echogenic continuous peripheral nerve block (cPNB) catheter and the AutoFuser® disposable pain pump can together provide clinicians with faster, more accurate catheter placement with a reliable, unimpeded infusion of medication.

The Arrow® FlexBlock® cPNB catheter’s coil-reinforced, polyurethane body is designed to help improve cPNB success by providing clinicians with an echogenic catheter—visible under ultrasound—which also resists kinking. The result: a cPNB catheter designed to help better control your patient’s pain and improve overall block success.

The AutoFuser disposable pain pump offers a combination of a continuous hands-free medication infusion with an optional on-demand patient-controlled bolus to immediately address breakthrough pain.

AT A GLANCE ADDRESS 155 South Limerick Road Limerick, PA 19468

PRODUCTS LMA® Airways, Rusch® EZ-Blocker™ Endobronchial Blocker, Rusch® ET Tubes and Laryngoscopes, ISO-Gard® Mask with ClearAir™ Technology, Arrow® Pain Management

EMPLOYEES 11,700

CHIEF EXECUTIVE OFFICER Benson Smith

Green Rusch Lite™ and Rusch® EquipLite™ disposable metal laryngoscope blades are single-use blades that offer users the performance and feel of a reusable metal blade. These blades eliminate the hassles associated with reusable blades, including the time and cost of reprocessing, without sacrificing strength or light quality.

Limiting Waste Anesthetic Gas Exposure In the PACU An invisible risk exists in the postanesthesia care unit (PACU). Patients are exhaling waste anesthetic gas into the breathing zone of their attending nurses,3 and although it cannot be detected by sight or odor, PACU clinicians can take action to protect themselves from the potential health effects.

The first of its kind, the ISO-Gard® mask with ClearAir™ technology was developed by Teleflex in partnership with clinicians who identified the issue and wanted to take action. As the only solution available for “source control” of waste gases, the specialized ClearAir™ technology of the ISO-Gard® mask simultaneously delivers oxygen to patients and scavenges their exhalation to help limit exposure faced by clinicians.

References Reducing Cross-Contamination, Reducing Cost The risk for cross-contamination during intubation of the trachea exists because no perfect procedure for decontamination exists. 2 Single-use devices offer the opportunity to reduce potential for infection associated with reusable devices.

1. Mungroop H, Wai PTJ, Morei NM, Loef BG, Epema AH. Lung isolation with a new Y shaped bronchial blocker, the EZ-Blocker. Br J Anaesth. 2009;104:119-120.

2. Disposable laryngoscope blades do not interfere with ease of intubation in scheduled general anesthesia patients. Eur J Anaesthesiol.

2003;20:731-735.

3. Occupational Safety and Health Administration, U.S. Department of Labor. Anesthetic gases: guidelines for workplace exposures. Revised 18 May 2000. http://www.osha.gov/dts/osta/anestheticgases/.

EquipLite is a trademark of Truphatek International Ltd. AutoFuser is a registered trademark of Ace Medical Co., Ltd. Teleflex, Arrow, ClearAir, EZ-Blocker, FlexBlock, Green Rusch Lite, Hudson RCI, ISO-Gard, LMA, LMA Airway Management, LMA Atomization, LMA Better by Design, LMA Supreme, MAD Nasal, MADgic, MADgic Airway and Rusch are trademarks or registered trademarks of Teleflex Incorporated or its affiliates.

This corporate profile was reviewed and approved by Teleflex.

THE INNOVATIVE WAY TO MAKE LUNG ISOLATION EASIER. ®

RUSCH EZ-BLOCKER

TM

The next generation in one-lung ventilation.

The EZ-Blo ocker™ Endobron nchial Blocker B r is the next generation n of one-lung ventii lation produccts designed tto enhance pa atient outcomes during selectivve procedures.

For more in nformation visit EZ-Bloc cker.co om.

INNOVAT IV E

IN T UIT IV E

SECUR E

The EZ-Blocker Endobronchial Blocker was developed by an anesthesiologist for use by anesthesiologists to provide an improved device for lung isolation. The EZ-Blocker Endobronchial Blocker has an innovative Y-shaped distal end that mirrors the bifurcation of the trachea which allows for intuitive, secure placement for lung isolation procedures.

Teleflex, EZ-Blocker and Rusch are trademarks or registered trademarks of Teleflex Incorporated or its affiliates. © 2013 Teleflex Incorporated. All rights reserved. 2013-1981

Read the #1 anesthesiology publication in the country anywhere, anytime.

August 2013 pg. 1 of 56